3-环戊基-3-氧代丙酸乙酯 | 24922-00-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 酮酸及其衍生物
• 中文名称: 3-环戊基-3-氧代丙酸乙酯
• 英文名称: ethyl 3-cyclopentyl-3-oxopropionate
• 英文别名: ethyl 3-cyclopentyl-3-oxopropanoate；3-cyclopentyl-3-oxopropionic acid ethyl ester
• CAS: 24922-00-7
• 化学式: C₁₀H₁₆O₃
• 分子量: 184.235
• InChiKey: MUDKQMLLCRJCEY-UHFFFAOYSA-N

物化性质

• 沸点：
  91-94 °C(Press: 1.8 Torr)
• 密度：
  1.065±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  13
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  43.4
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2918300090
• 危险性防范说明：
  P305+P351+P338
• 危险性描述：
  H227,H315,H319,H335
• 储存条件：
  室温且干燥

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 3-Cyclopentyl-3-oxo-propionic acid ethyl ester
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 3-Cyclopentyl-3-oxo-propionic acid ethyl ester
CAS number: 24922-00-7

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C10H16O3
Molecular weight: 184.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

用途

3-环戊基-3-氧代丙酸乙酯可用作医药合成中间体。

危险处理

如吸入3-环戊基-3-氧代丙酸乙酯，请将患者移至新鲜空气处；若皮肤接触，应脱去污染衣物，并用肥皂水和清水彻底清洗皮肤，如有不适，请就医；如眼睛接触，应翻开眼睑，用流动清水或生理盐水冲洗，并立即就医；如误食，应立即漱口，禁止催吐，并尽快就医。

反应信息

• 作为反应物：
  描述：

  3-环戊基-3-氧代丙酸乙酯 在 potassium tert-butylate 、 四乙基氯化铵 、 N,N-二异丙基乙胺 、 三氯氧磷 作用下， 以 甲醇 、 乙腈 为溶剂， 反应 0.33h， 生成 4-氯-6-环戊基嘧啶-2-胺
  参考文献：
  名称：

  Discovery and SAR of 6-Alkyl-2,4-diaminopyrimidines as Histamine H₄ Receptor Antagonists

  摘要：

  This report discloses the discovery and SAR of a series of 6-alkyl-2-aminopyrimidine derived histamine H4 antagonists that led to the development of JNJ 39758979, which has been studied in phase II clinical trials in asthma and atopic dermatitis. Building on our SAR studies of saturated derivatives from the indole carboxamide series, typified by JNJ 7777120, and incorporating knowledge from the tricyclic pyrimidines led us to the 6-alkyl-2,4-diaminopyrimidine series. A focused medicinal chemistry effort delivered several 6-alkyl-2,4-diaminopyrimidines that behaved as antagonists at both the human and rodent H4 receptor. Further optimization led to a panel of antagonists that were profiled in animal models of inflammatory disease. On the basis of the preclinical profile and efficacy in several animal models, JNJ 39758979 was selected as a clinical candidate; however, further development was halted during phase II because of the observation of drug-induced agranulocytosis (DIAG) in two subjects.

  DOI：

  10.1021/jm401727m
• 作为产物：
  描述：

  环戊基甲酰氯 在 吡啶 作用下， 以 二氯甲烷 、 甲苯 为溶剂， 反应 26.0h， 生成 3-环戊基-3-氧代丙酸乙酯
  参考文献：
  名称：

  作为选择性 A3 腺苷受体拮抗剂的 3, 5-二酰基-2,4-二烷基吡啶衍生物的结构-活性关系和分子建模。

  摘要：

  已经探索了作为人A3腺苷受体选择性拮抗剂的6-苯基-1,4-二氢吡啶衍生物的结构-活性关系(Jiang等人J.Med.Chem.1997, 39, 4667-4675)。在本研究中，已经合成了相关的吡啶衍生物，并在放射性配体结合测定中测试了对腺苷受体的亲和力。对于某些 3,5-二酰基-2,4-二烷基-6-苯基吡啶衍生物在取代 [125I]AB-MECA (N6-(4-氨基-3-碘苄基)-5' 时观察到纳摩尔范围内的 Ki 值-N-甲基氨基甲酰基腺苷）位于重组人 A3 腺苷受体上。确定 A3 腺苷受体的选择性与大鼠脑 A1 和 A2A 受体上放射性配体的结合。探讨了吡啶环不同位置（3-和5-酰基取代基以及2-和4-烷基取代基）的结构-活性关系。与 4-取代的二氢吡啶不同，4-苯基乙炔基不会增强吡啶衍生物的 A3 选择性。在2-位和4-位，乙基优于甲基。此外，与二氢吡啶不同，3位的硫酯基团比酯

  DOI：

  10.1021/jm980093j

文献信息

• [EN] HEPATITIS B CAPSID ASSEMBLY MODULATORS<br/>[FR] MODULATEURS D'ASSEMBLAGE DE CAPSIDE DE L'HÉPATITE B
  申请人：VENATORX PHARMACEUTICALS INC

  公开号：WO2021119081A1

  公开（公告）日：2021-06-17

  Described herein are hepatitis B capsid assembly modulators and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of hepatitis B.

  本文描述了乙型肝炎壳蛋白组装调节剂和包含该类化合物的药物组合物。这些化合物和组合物对于治疗乙型肝炎是有用的。
• The Preparation of Some Substituted Thiohydantoins and Thioimidazoles
  作者：Mary Jackman、Mabel Klenk、B. Fishburn、B. F. Tullar、S. Archer

  DOI：10.1021/ja01189a015

  日期：1948.9

  It has been shown that proper substitution a t the six position in 2-thiouracil resulted in increased antithyroid activity.' Astwood showed that 2thiohydantoin was half and 2-thioimidazole one and one half times as active as 2-thiouracil in goitrogenic potency.2 It seemed likely then that appropriately substituted thiohydantoins and thioimidazoles would show greater activity than the parent heterocycles

  已经表明，在 2-硫尿嘧啶的第 6 个位置上的适当取代导致抗甲状腺活性增加。Astwood 表明，在致甲状腺肿的效力方面，2-硫代乙内酰脲的活性是 2-硫代乙内酰脲的一半，而 2-硫代咪唑的活性是 2-硫尿嘧啶的二分之一。2 看来，适当取代的硫代乙内酰脲和硫代咪唑可能比母体杂环表现出更大的活性。因此，已经制备了许多用于药理学筛选的 5-烷基-2-硫代乙内酰脲和 4-烷基-2-硫代咪唑。Wheeler 和同事通过氨基酸和硫氰酸铵在乙酸酐中的相互作用制备了烷基硫代乙内酰脲，首先得到 l-乙酰基-5-烷基-2 硫代乙内酰脲，它在与盐酸一起煮沸时失去乙酰基. 大多数需要的氨基酸是通过Albert-on的方法制备的。在所有情况下，中间乙酰基体未经纯化就进行水解裂解。在遇到油性乙酰硫代乙内酰脲的少数情况下，淬灭的反应混合物用氯仿萃取，并如实验部分所述进行进一步处理。4-烷基-2-硫代咪唑是由相应的氨基
• [EN] METHOD FOR THE USE OF PYRANOINDOLE DERIVATIVES TO TREAT INFECTION WITH HEPATITIS C VIRUS<br/>[FR] METHODE D'UTILISATION DE DERIVES DU PYRANOINDOLE POUR TRAITER UNE INFECTION PAR LE VIRUS DE L'HEPATITE C
  申请人：WYETH CORP

  公开号：WO2003099275A1

  公开（公告）日：2003-12-04

  The invention is directed to methods of treating, preventing, or inhibiting a Hepatitis C viral infection in a mammal comprising containing the mammal with an effective amount of a compound of the formula: Wherein substitutions at R1, R2, R3-R12, and Y are set forth in the specification.

  这项发明涉及治疗、预防或抑制哺乳动物体内丙型肝炎病毒感染的方法，包括使用有效量的符合以下结构式的化合物来处理哺乳动物：其中R1、R2、R3-R12和Y的取代基在说明书中列出。
• Modular Tuning of Electrophilic Reactivity of Iridium Nitrenoids for the Intermolecular Selective α-Amidation of β-Keto Esters
  作者：Minhan Lee、Hoimin Jung、Dongwook Kim、Jung-Woo Park、Sukbok Chang

  DOI：10.1021/jacs.0c04344

  日期：2020.7.15

  herein an Ir-catalyzed intermolecular amino group transfer to β-keto esters (amides) to access α-aminocarbonyl products with excellent chemoselectivity. The key strategy was to engineer electrophilicity of the putative Ir-nitrenoids by tuning electronic property of the κ2-N,O chelating ligands, thus facilitating nucleophilic addition of enol π-bonds of 1,3-dicarbonyl substrates.

  我们在此报告了 Ir 催化的分子间氨基转移到 β-酮酯（酰胺）以获取具有优异化学选择性的 α-氨基羰基产物。关键策略是通过调节 κ2-N,O 螯合配体的电子特性来设计假定的 Ir-nitrenoids 的亲电性，从而促进 1,3-二羰基底物的烯醇 π 键的亲核加成。
• [EN] BIARYL PYRAZOLES AS NRF2 REGULATORS<br/>[FR] BIARYL PYRAZOLES UTILISÉS COMME RÉGULATEURS DE NRF2
  申请人：GLAXOSMITHKLINE IP DEV LTD

  公开号：WO2017060854A1

  公开（公告）日：2017-04-13

  The present invention relates to biaryl pyrazole compounds, methods of making them, pharmaceutical compositions containing them and their use as NRF2 regulators.

  本发明涉及双芳基吡唑化合物、它们的制备方法、含有它们的药物组合物及其作为NRF2调节剂的应用。